<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448654</url>
  </required_header>
  <id_info>
    <org_study_id>1504015628</org_study_id>
    <secondary_id>1R21DA038253-01A1</secondary_id>
    <nct_id>NCT02448654</nct_id>
  </id_info>
  <brief_title>Treatment for Nicotine Addiction in Women</brief_title>
  <official_title>COMT Inhibition as a Novel Treatment for Nicotine Addiction in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use a medication tolcapone and or placebo to test if the
      symptoms of nicotine withdrawal lessens , and or changes in smoking urges, and mental
      reasoning in female smokers over a 72 hour period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed trail will be use a double-blind, placebo-controlled design to conduct the first
      randomized controlled trial of the COMT inhibitor, tolcapone, in nicotine dependent women.
      This study will determine if tolcapone is superior to placebo by attenuation the severity of
      nicotine withdrawal and smoking urges during short-term abstinence. Withdrawal severity will
      be assessed by a self-report scale and cognitive assessment, including a sustained-attention
      task. Smoking urges will be assessed by a self-report scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2015</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Test medication groups for withdrawal</measure>
    <time_frame>7 days</time_frame>
    <description>smoking scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Tolcapone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg tolcapone three times a day for 7 days then 100mg once a day on day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone</intervention_name>
    <description>Tolcapone will be compared to sugar pill</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>Tasmar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>The sugar pill (placebo) will be compared to tolcapone</description>
    <arm_group_label>Tolcapone</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18yrs to 45yr old woman, read and write in English.

          -  Must smoke at least 5 or more cigarettes a day

          -  FTND score at least 4 or higher

          -  A CO reading of 10 or higher during screening

          -  Must be in good health as verified by medical history, screening exam, screen
             laboratory tests.

        Exclusion Criteria:

          -  Excluded if using psychotropic medications, have contraindications to tolcapone use
             (e.g.. liver problems, allergy to tolcapone, history of no traumatic rhabdomyolysis or
             hyperpyrexia, confusion possibly related to medication), have other substance use
             disorder, are pregnant or breast feeding, have a current psychotic disorder, bipolar
             disorder, homicidal or suicidal ideation, have current (past month) substance use
             disorder, other than nicotine dependence, or are unable to fulfill the scheduled
             visits and procedures.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elise DeVito, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Administration Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

